Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123456>>>
150 Items
Title  Creator  Group name  Publishing year 
Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches Abba Moussa et al. EquipePM 2025-12
[Contribution of intraperitoneal chemotherapy in the treatment of colorectal peritoneal carcinoma. HIPEC, PIPAC, state of the art and future directions] Quénet et al. EquipePM 2024-03
Impact of obesity after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for rare peritoneal malignancies: Paradox of obesity or poor prognostic factor? Aubert et al. EquipePM 2024-06-25
Identification of monoclonal antibodies from naive antibody phage-display libraries for protein detection in formalin-fixed paraffin-embedded tissues Mairaville et al. EquipePM 2024-07-25
Hyperthermic intraperitoneal chemotherapy in colorectal cancer Fisher et al. EquipePM 2024-05-08
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial Classe et al. EquipePM 2024-12
Generation of non-genetically modified, CAR-like, NK cells Coënon et al. EquipePM 2024-07-18
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study Trecourt et al. EquipePM 2024-05
ASO Visual Abstract: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy to Treat Pseudomyxoma Peritonei of Ovarian Origin: A Retrospective French RENAPE Group Study Trecourt et al. EquipePM 2024-02-09
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipePM 2024-01-30
A bioinspired approach for the modulation of electroosmotic flow and protein-surface interactions in capillary electrophoresis using silylated amino-amides blocks and covalent grafting Gouyon et al. EquipePM 2024-03
Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepato-biliary scintigraphy the optimal tool? Cusumano et al. EquipePM 2023-03-15
Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched study Cashin et al. EquipePM 2023-01
Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody Noverraz et al. EquipePM 2023-01-05
Liver Venous Deprivation Versus Portal Vein Embolization Before Major Hepatectomy for Colorectal Liver Metastases: A Retrospective Comparison of Short- and Medium-Term Outcomes Cassese et al. EquipePM 2023-02
Fc-engineered monoclonal antibodies to reduce off-target liver uptake Mangeat et al. EquipePM 2023-09-11
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer David et al. EquipePM 2023-11-29
Activation of neuronal FLT3 promotes exaggerated sensorial and emotional pain-related behaviors facilitating the transition from acute to chronic pain Tassou et al. EquipePM 2023-01-13
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies Antunes et al. EquipePM 2023
Upregulated flotillins and sphingosine kinase 2 derail AXL vesicular traffic to promote epithelial-mesenchymal transition Genest et al. EquipePM 2022-04-01
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases Giguelay et al. EquipePM 2022
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases Khellaf et al. EquipePM 2022-11
Targeting the splicing isoforms of spleen tyrosine kinase affects the viability of colorectal cancer cells Denis et al. EquipePM 2022
Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort Carbasse et al. EquipePM 2022-07
Oncogenic Signalling of PEAK2 Pseudokinase in Colon Cancer Lecointre et al. EquipePM 2022-06-16
123456>>>
150 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés